The DOI matches its Crossref record.
The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease
Abstract
Current treatment of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia and hyperphosphatemia. AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) synthesis and secretion by increasing the sensitivity of the parathyroid calcium-sensing receptor (CaR) to extracellular calcium. The current study evaluates the efficacy and safety of AMG 073 when added to conventional treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD). Seventy-one hemodialysis patients with uncontrolled secondary hyperparathyroidism, despite standard therapy with calcium, phosphate binders, and active vitamin D sterols, were treated in this 18-wk, dose-titration study with single daily oral doses of AMG 073/placebo up to 100 mg. Changes in plasma PTH, serum calcium, serum phosphorus, and calcium x phosphorus levels were compared between AMG 073 and placebo groups. Mean PTH decreased by 33% in the AMG 073 patients compared with an increase of 3% in placebo patients (P = 0.001). A significantly greater proportion of AMG 073 patients (44%) had a mean PTH < or = 250 pg/ml compared with placebo patients (20%; P = 0.029). Also, a significantly greater proportion of AMG 073 patients (53%) had a decrease in PTH > or =30% compared with placebo patients (23%; P = 0.009). Calcium x phosphorus levels decreased by 7.9% in AMG 073 patients compared with an increase of 11.3% in placebo patients (P = 0.013). Adverse event rates were low and mostly mild to moderate in severity; however, the incidence of vomiting was higher in AMG 073 patients. In this study, the calcimimetic AMG 073 at doses up to 100 mg for 18 wk provided a safe and effective means to attain significant reductions in PTH and calcium x phosphorus levels in ESRD patients. AMG 073 represents a novel and promising therapy to improve the management of secondary hyperparathyroidism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cunningham, J., Danese, M., Olson, K., Klassen, P., & Chertow, G. M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00596.x · Cited by 566
Peacock, M., Bilezikian, J. P., Klassen, P. S., Guo, M. D., Turner, S. A., & Shoback, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0842 · Cited by 471
Self-citationLindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060512 · Cited by 413
Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl
Nemeth, E. F., Heaton, W. H., Miller, M., Fox, J., Balandrin, M. F., Van Wagenen, B. C., Colloton, M., Karbon, W., Scherrer, J., Shatzen, E., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057273 · Cited by 369
Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
Moe, S. M., Chertow, G. M., Coburn, J. W., Quarles, L. D., Goodman, W. G., Block, G. A., DrEke, T. B., Cunningham, J., Sherrard, D. J., Mccary, L. C., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67139.x · Cited by 327
Self-citation
Metadata
- Authors
- Quarles, L. D., Sherrard, D. J., Adler, S., Rosansky, S. J., McCary, L. C., Liu, W., Turner, S. A., & Bushinsky, D. A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2003-03
- Volume
- 14
- Issue
- 3
- Pages
- 575-583
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2121613126
- Cited by
- 248
- References
- 0
- FWCI
- 19.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease. https://app.cochat.ai/papers/10.1097/01.asn.0000050224.03126.ad
- The paper
- Quarles, L. D., Sherrard, D. J., Adler, S., Rosansky, S. J., McCary, L. C., Liu, W., Turner, S. A., & Bushinsky, D. A. (2003). The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000050224.03126.ad
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.